HylaPharm is an exciting start-up led by KU’s Daniel Aires, M.D., J.D. – Stiefel professor and director of the division of dermatology and Laird Forrest, Ph.D. - associate professor of pharmaceutical chemistry. Their company has a novel drug-delivery technology that makes treatment of certain types of cancer, including breast cancer and head and neck cancer, both safer and more effective. Using their innovative delivery system (HylaPlat), chemotherapy can be delivered directly into a tumor mass, after which it penetrates into the lymph nodes where cancers typically spread.
For more information, visit hylapharm.com.